Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30375308 | 0.84 | F11 (0.46) | — | |
| SCHEMBL12465733 | 0.83 | MCL1 (0.51) | KDM4EALDH1A1HSD17B10MCL1PTGER1 | |
| SCHEMBL22777747 | 0.82 | ALDH1A1 (0.58) | KDM4EALDH1A1HSD17B10KMOLDHA | |
| SCHEMBL3561838 | 0.81 | MAPT (0.55) | KDM4EALDH1A1HSD17B10POLBL3MBTL1 | |
| SCHEMBL23998389 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10PTGS1MCL1 | |
| SCHEMBL13500768 | 0.79 | RAB9A (0.46) | ALDH1A1MAPT | |
| SCHEMBL16619771 | 0.79 | APOBEC3A (0.41) | KDM4EALDH1A1LDHAPTGS1PTGS2 | |
| SCHEMBL17141136 | 0.79 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10PTGS1PTGS2 | |
| SCHEMBL20723052 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1PTGS1PTGS2APOBEC3A | |
| SCHEMBL20723260 | 0.78 | MAPT (0.45) | KDM4EALDH1A1HSD17B10PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1505068-A1 | PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | NADK, PNPO, NQO1 | KDM4E 3108/4885ALDH1A1 85/4885HSD17B10 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.